^
Association details:
| Biomarker: | SRSF2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ATR/CHK1/WEE1 Dependency in SRSF2-Mutated MDS/AML
Published date:
11/04/2021
Excerpt:
Analysis of ex vivo drug sensitivities in AML patient samples identified vulnerability to CHK1 and WEE1 inhibition in SRSF2-mutated AML: SRSF2 mutation is associated with sensitivity to the CHK1 inhibitors prexasertib (p = 0.006) (Fig 1 A and B) and PF-00477736 (p = 0.002) and the WEE1 inhibitor adavosertib (p = 0.003).
DOI:
10.1182/blood-2021-147960
